STAK Inc. gets Nasdaq $1.00 bid price notice; 180-day cure
STAK Inc. reported it received a Nasdaq notice that its Class A ordinary shares are below the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2).
Rhea-AI Filing Summary
STAK Inc. reported it received a Nasdaq notice that its Class A ordinary shares are below the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2). The company has an initial 180-day compliance period until April 13, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days.
If unmet by that date, STAK may qualify for an additional 180-day period if it meets other Nasdaq Capital Market standards and notifies Nasdaq of its plan to cure, which may include a reverse stock split. The notice does not affect business operations, and the company will monitor its share price.
Positive
- None.
Negative
- None.
Insights
Compliance notice starts a defined cure timeline.
STAK Inc. disclosed a Nasdaq bid-price deficiency. Under Rule 5810(c)(3)(A), it has 180 days, until April 13, 2026, to achieve a closing bid of at least $1.00 for 10 consecutive business days.
Failure to meet this initial window may allow a second 180-day period if the company meets other initial listing standards and formally indicates a cure path, potentially via a reverse stock split. Actual outcomes depend on share price performance and eligibility.
The company states operations are unaffected. A key milestone is the initial deadline on April 13, 2026; subsequent steps, including any appeal of a delisting determination, would follow Nasdaq procedures if needed.
AI-generated analysis. How Rhea-AI works. Not financial advice.